Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside
8.0
来源：
Nature
关键字：
multi-omics
发布时间：
2025-11-17 23:46
摘要：
Drug-tolerant persister cells (DTPs) are a significant challenge in achieving lasting cancer remission due to their ability to survive standard therapies. This article discusses the biological characteristics of DTPs, including their adaptive mechanisms and the need for innovative research approaches that integrate clinical complexities. It highlights the importance of understanding DTPs to develop effective therapies and actionable biomarkers, ultimately aiming to bridge the gap between laboratory research and clinical application.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
DTPs represent a major obstacle to achieving durable cancer remission.
The article emphasizes the need to move beyond reductionist models toward integrative, patient-aligned approaches.
Bridging the divides will be crucial to reveal actionable biomarkers and develop therapies capable of eradicating these resilient cell populations.
真实性检查
否
AI评分总结
Drug-tolerant persister cells (DTPs) are a significant challenge in achieving lasting cancer remission due to their ability to survive standard therapies. This article discusses the biological characteristics of DTPs, including their adaptive mechanisms and the need for innovative research approaches that integrate clinical complexities. It highlights the importance of understanding DTPs to develop effective therapies and actionable biomarkers, ultimately aiming to bridge the gap between laboratory research and clinical application.